Travis Whitfill

Chief Operating Officer

2023 - Current

Assistant Professor Adjunct

2022

My research in pediatrics involves the use of technology and innovative techniques to improve the quality and safety of care through work at the level of individual providers, teams of providers, and teams of providers working within complex systems. The research interest relies on the use of simulation as a research methodology. I have developed analytical techniques to use simulation-based assessments to describe differences in care across a large spectrum of Emergency Departments. I co-designed, analyzed, and reported on a large 30-center study examining differences in care across hospitals in the northeast and mid-Atlantic US and am working with Pediatric Emergency Medicine physicians to expand this effort to measure and compare the quality of pediatric acute care across a larger geographic region. I am also interested in applying this work in the prehospital setting, particularly with disaster triage.

Associate Research Scientist

2017 - 2022

My research in pediatrics involves the use of technology and innovative techniques to improve the quality and safety of care through work at the level of individual providers, teams of providers, and teams of providers working within complex systems. The research interest relies on the use of simulation as a research methodology. I have developed analytical techniques to use simulation-based assessments to describe differences in care across a large spectrum of Emergency Departments. I co-designed, analyzed, and reported on a large 30-center study examining differences in care across hospitals in the northeast and mid-Atlantic US and am working with Pediatric Emergency Medicine physicians to expand this effort to measure and compare the quality of pediatric acute care across a larger geographic region. I am also interested in applying this work in the prehospital setting, particularly with disaster triage.

Board Member

2018

Entrepreneur In Residence

2018

Senior Analyst

2014

I am the senior analyst for a an equities research firm that specializes in the healthcare, pharmaceutical, and biotechnology industries. Our main clients are hedge funds and institutional investors.

Partner

2015 - 2023

We invest in early-stage healthcare technologies that have potential to be transformative to healthcare. Our portfolio companies include Encore Vision (acquired), 410 Medical Inc., Azitra Inc., Cognition Therapeutics, Incysus Therapeutics, Lantern Pharmaceuticals Inc., Lung Therapeutics Inc., Abilitech Medical Inc., and Actuate Therapeutics Inc. Our first exit was Encore Vision, which was acquired by Novartis for an undisclosed total amount that provided $375M on the upfront payment. My role is focused on business development and strategy, clinical development, due diligence, and deal sourcing and evaluation. Boards: Azitra Inc., 410 Medical, Immusoft Corporation (observer), Incysus Therapeutics

Cofounder and Executive Director of Advanced Technology

2019 - 2022

Cofounder and Chief Science Officer

2014 - 2019

We're modulating the skin microbiome to treat skin disease. Aiming to create a new paradigm in drug delivery by re-engineering commensal skin bacteria to influence the human microbiome and secrete biologics for therapeutic purposes. We've raised about $7 million with the support of the NIH, NSF, Department of Defense, Bios Partners, and Connecticut Innovations. We expect to bring our lead asset, AZT-01 for atopic dermatitis, into clinical studies beginning in 2018. See more at @azitrainc or http://www.azitrainc.com/

Research Associate

2012 - 2016

Instructor

2013 - 2014

Territory Sales Manager

2012 - 2012

Expanded Bio Basic Inc., a Canadian life science supplier, into Texas and Oklahoma and led territory to become most profitable in the United States.